LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Inicio・Lista de Acciones・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Cerrado

SectorSanidad

9.94 1.64

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.62

Máximo

9.98

Métricas clave
By Trading Economics
Ingresos	42M 17M
Ventas	14M 169M
BPA	0.17
Margen de beneficios	10.237
Empleados	499
EBITDA	54M 48M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+62.37% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	678M 3B
Apertura anterior	8.3
Cierre anterior	9.94

Noticias sobre sentimiento de mercado

By Acuity

100%

358 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.925 / 7.38 Soporte y Resistencia

Amicus Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 dic 2025, 20:41 UTC

Ganancias

Principales Movimientos del Mercado

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4 dic 2025, 18:14 UTC

Adquisiciones, fusiones, absorciones

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4 dic 2025, 17:43 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4 dic 2025, 17:01 UTC

Ganancias

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4 dic 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4 dic 2025, 23:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 dic 2025, 21:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 dic 2025, 21:54 UTC

Charlas de Mercado

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4 dic 2025, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

4 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 dic 2025, 21:48 UTC

Charlas de Mercado

Scales Hits Mark With Earnings Guidance -- Market Talk

4 dic 2025, 21:37 UTC

Ganancias

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4 dic 2025, 21:36 UTC

Ganancias

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4 dic 2025, 20:15 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 dic 2025, 20:15 UTC

Charlas de Mercado

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4 dic 2025, 20:04 UTC

Charlas de Mercado

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4 dic 2025, 19:54 UTC

Charlas de Mercado

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4 dic 2025, 19:44 UTC

Adquisiciones, fusiones, absorciones

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4 dic 2025, 19:44 UTC

Adquisiciones, fusiones, absorciones

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4 dic 2025, 19:44 UTC

Adquisiciones, fusiones, absorciones

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4 dic 2025, 19:33 UTC

Charlas de Mercado

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4 dic 2025, 19:01 UTC

Adquisiciones, fusiones, absorciones

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4 dic 2025, 19:01 UTC

Adquisiciones, fusiones, absorciones

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4 dic 2025, 19:01 UTC

Adquisiciones, fusiones, absorciones

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4 dic 2025, 19:01 UTC

Adquisiciones, fusiones, absorciones

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4 dic 2025, 18:58 UTC

Charlas de Mercado

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 dic 2025, 16:41 UTC

Charlas de Mercado

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4 dic 2025, 16:33 UTC

Charlas de Mercado

Ganancias

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Comparación entre iguales

Cambio de precio

Amicus Therapeutics Inc previsión

Precio Objetivo

By TipRanks

62.37% repunte

Estimación a 12 Meses

Media 15.88 USD 62.37%

Máximo 21 USD

Mínimo 11 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amicus Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Amicus Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.925 / 7.38Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

358 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.